ClinicalTrials.gg

Program

FXS887

A development code.

Its studies are led by Fosun Pharma.

Furthest: phase 1, since Dec 23, 20251 company-led study, 1 open or runningNext primary completion: Apr 28, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Dec 23, 2025Dec 23, 2025Apr 28, 2027phase 1 · NCT07345637

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2025First study: phase 1 study in Solid Tumor Refractory to Conventional TreatmentFirst studyNCT07345637 · 14 planned · China

Ahead

  1. Apr 28, 2027Primary completion: phase 1 study in Solid Tumor Refractory to Conventional TreatmentNCT07345637

TargetBeta

ATR →read by rule
“FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.”study text, by rule · the study

Other programs on ATR

ProgramCompanyFurthest phaseStudies
ceralasertibruleAstraZenecaphase 316
TCC1727Sino Biopharmaceuticalphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07345637Solid Tumor Refractory to Conventional Treatment · China1Not yet recruitingApr 28, 202714

How it is read

Names in the registry

  • “FXS887”, 1 entry

Codes read as this program: FXS887.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.